In this review:
Mortality and cancer in paediatric IBD
Faecal calprotectin with infliximab for UC
Anti-TNF-α therapy a cost driver in IBD
Predictors of long-term efficacy of infliximab in UC
Adenomas and advanced neoplasia risk in IBD
Immunosuppressive co-treatment with adalimumab
Ciprofloxacin plus adalimumab for fistula closure
Cyclosporin A rescue therapy for steroid-refractory UC
Adalimumab for perianal CD
Infliximab for distal refractory UC
Effective smoking cessation in CD patients
Restart rate after biologic treatment cessation
Download PDF